10 Years of the Antigen-Specific Immune Tolerance Summit Panel Discussion: Assessing this Year’s Presentations & Defining the Next Steps in Immune Tolerance Research for Clinical Success

• Evaluating the novel mechanistic insights from this year’s program
• Assessing the preclinical data shared and looking to the next year’s clinical therapeutic landscape
• Supercharging antigen-specific immune tolerance therapies to the clinic – what can the field do together to make the promise of the technology a reality?

Speakers:

Anders Essen-Möller

Chief Executive Officer

Diamyd

Joseph Podojil

Director of Immunology

Cour Pharmaceuticals Development Co., Inc.

Charlotte Fribert

Chief Executive Officer

Bonsai Biotherapeutics